Page last updated: 2024-10-21

4-carboxy-3-hydroxyphenylglycine and Autosomal Dominant Juvenile Parkinson Disease

4-carboxy-3-hydroxyphenylglycine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 1 studies

4-carboxy-3-hydroxyphenylglycine: weak agonist at metabotropic glutamate receptors; occludes the action of 1-aminocyclopentyl-1,3-dicarboxylate in hippocampus

Research Excerpts

ExcerptRelevanceReference
"The aim of the present study was to determine whether S-4-carboxy-3-hydroxyphenylglycine (S)-4C3HPG, a mixed group I glutamate metabotropic receptor antagonist and a group II agonist, attenuated parkinsonian-like muscle rigidity in rats."3.71(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lorenc-Koci, E1
Wardas, J1
Wolfarth, S1
Pilc, A1

Other Studies

1 other study available for 4-carboxy-3-hydroxyphenylglycine and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
    Brain research, 2001, Jun-08, Volume: 903, Issue:1-2

    Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine;

2001